{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:02:09Z","timestamp":1791918129510,"version":"4.3.4"},"reference-count":36,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2020,6,23]]},"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1136\/ejhpharm-2019-002106","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T17:45:13Z","timestamp":1595958313000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Discontinuation of cholinesterase inhibitor treatment in institutionalised patients with advanced dementia"],"prefix":"10.1136","volume":"29","author":[{"given":"Ram\u00f3n","family":"Garc\u00eda-Garc\u00eda","sequence":"first","affiliation":[{"name":"Pharmacy, Hospital Universitario de Torrevieja, Torrevieja, Spain"},{"name":"University of Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Calleja-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"University of Granada, Granada, Spain"},{"name":"Virgen Macarena University Hospital, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"2025090702525372000_29.3.145.1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-55"},{"key":"2025090702525372000_29.3.145.2","unstructured":"National Institute for Health and Clinical Excellence . Dementia: assessment, management and support for people living with dementia and their carers. London, 2018. Available: http:\/\/www.nice.org.uk\/guidance\/ng97 [Accessed 15 Feb 2019]."},{"key":"2025090702525372000_29.3.145.3","unstructured":"Fern\u00c3\u00a1ndez M , Blesa R , Demencia ZJJ Zarranz JJ , ed. Neurology. Fourth edition. Madrid: Elsevier Science, 2008."},{"key":"2025090702525372000_29.3.145.4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.2.137"},{"key":"2025090702525372000_29.3.145.5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000367889","article-title":"The acetylcholine index: an electroencephalographic marker of cholinergic activity in the living human brain applied to Alzheimer's disease and other dementias","volume":"39","author":"Johannsson","year":"2015","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2025090702525372000_29.3.145.6","unstructured":"National Institute for Health and Clinical Excellence . Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London,, 2011. Available: https:\/\/www.nice.org.uk\/guidance\/TA217 [Accessed 15 Feb 2019]."},{"key":"2025090702525372000_29.3.145.7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5694\/mja2.50015","article-title":"Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary","volume":"210","author":"Reeve","year":"2019","journal-title":"Med J Aust"},{"key":"2025090702525372000_29.3.145.8","unstructured":"Working Group of the Clinical Practice Guideline on comprehensive care for people with Alzheimer's disease and other dementias . Clinical practice guideline on comprehensive care for people with Alzheimer's disease and other dementias. quality plan for the National health system of the Ministry of health, social policy and equality. Catalan agency for information, evaluation and quality in health; 2010. clinical practice guides in the NHS: AIAQS N\u00c3\u00bam, 2009. Available: https:\/\/portal.guiasalud.es\/wp-content\/uploads\/2018\/12\/GPC_484_Alzheimer_AIAQS_resum.pdf- [Accessed 15 Feb 2019]."},{"key":"2025090702525372000_29.3.145.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3932(01)00055-0"},{"key":"2025090702525372000_29.3.145.10","first-page":"661","article-title":"Global deterioration scale (GDS)","volume":"24","author":"Reisberg","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"2025090702525372000_29.3.145.11","first-page":"317","article-title":"Neuropsychiatric inventory questionnaire (NPI-Q): Spanish validation of an abbreviated form of the neuropsychiatric inventory (NPI)","volume":"17","author":"Boada","year":"2002","journal-title":"Neurolog\u00c3\u00ada"},{"key":"2025090702525372000_29.3.145.12","doi-asserted-by":"publisher","DOI":"10.1590\/S1135-57271997000200004"},{"key":"2025090702525372000_29.3.145.13","doi-asserted-by":"publisher","DOI":"10.2217\/1745509X.4.3.311"},{"key":"2025090702525372000_29.3.145.14","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2607"},{"key":"2025090702525372000_29.3.145.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106668"},{"key":"2025090702525372000_29.3.145.16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110134","article-title":"Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial","volume":"26","author":"Scarpini","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"2025090702525372000_29.3.145.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2015.08.019"},{"key":"2025090702525372000_29.3.145.18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2045125313508130","article-title":"The influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe Alzheimer\u2019s disease with behavioral and psychological symptoms on dementia: a preliminary open-label trial","volume":"4","author":"Suzuki","year":"2014","journal-title":"Therapeutic Advances in"},{"key":"2025090702525372000_29.3.145.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181741","article-title":"Synergistic effects of cognitive impairment on physical disability in all-cause mortality among men aged 80 years and over: results from longitudinal older veterans study","volume":"12","author":"Yu","year":"2017","journal-title":"PLoS One"},{"key":"2025090702525372000_29.3.145.20","first-page":"292","article-title":"Prediction of treatment response to rivastigmine in Alzheimer's dementia","volume":"75","author":"Adler","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025090702525372000_29.3.145.21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000449244","article-title":"The effects of donepezil on 15-Item geriatric depression scale structure in patients with Alzheimer disease","volume":"6","author":"Yang","year":"2016","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"2025090702525372000_29.3.145.22","first-page":"124","article-title":"Study on the use of antidementia drugs in primary care","volume":"11","author":"Carracedo Mart\u00c3\u00adnez","year":"2009","journal-title":"Atencion Farmaceutica"},{"key":"2025090702525372000_29.3.145.23","article-title":"Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists","volume":"17","author":"Bentu\u00e9-Ferrer","year":"2003","journal-title":"CNS Drugs"},{"key":"2025090702525372000_29.3.145.24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/gerona\/glr233","article-title":"Shelter project","volume":"67","author":"Onder","year":"2012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2025090702525372000_29.3.145.25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3233\/JAD-170905","article-title":"Polypharmacy and potentially inappropriate medication in people with dementia: a nationwide study","volume":"63","author":"Kristensen","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2025090702525372000_29.3.145.26","unstructured":"Work group on Alzheimer's disease and other dementias . Practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Arlington, VA (US: American Psychiatric Association, 2007."},{"key":"2025090702525372000_29.3.145.27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.regg.2010.11.003","article-title":"Use of antipsychotics in patients with dementia","volume":"46","author":"Hereu","year":"2011","journal-title":"Rev Esp Geriatr\u00c3\u00ada Gerontol"},{"key":"2025090702525372000_29.3.145.28","unstructured":"Working Group of the Clinical Practice Guideline on Palliative Care . Clinical practice guideline on palliative care. Madrid: national plan for the sns of the MSC. Basque country health technology assessment agency; 2008. clinical practice guidelines in the sns: OSTEBA no 2006\/08. Available: http:\/\/www.guiasalud.es\/GPC\/GPC_428_Paliativos_Osteba_compl.pdf [Accessed 15 Feb 2019]."},{"key":"2025090702525372000_29.3.145.29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.rpsm.2016.11.003","article-title":"Trazodone utilization among the elderly in Spain. A population based study","volume":"11","author":"Mac\u00edas Saint-Gerons","year":"2018","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"2025090702525372000_29.3.145.30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jamda.2018.12.019","article-title":"Antipsychotic treatment associated with increased mortality risk in patients with dementia. A registry-based observational cohort study","volume":"20","author":"Schwertner","year":"2019","journal-title":"J Am Med Dir Assoc"},{"key":"2025090702525372000_29.3.145.31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0044-100523","article-title":"Prescription of benzodiazepines and related drugs in patients with mild cognitive deficits and Alzheimer's disease","volume":"52","author":"Hessmann","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"2025090702525372000_29.3.145.32","unstructured":"McIntosh B , Clark M , Spry C . Benzodiazepines in Older Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2011. Appendix 5, summary of guidelines addressing the use of benzodiazepines in the elderly. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK174568\/ [Accessed 15 Feb 2019]."},{"key":"2025090702525372000_29.3.145.33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40266-017-0502-6","article-title":"Anticholinergic prescribing in Medicare Part D beneficiaries residing in nursing homes: results from a retrospective cross-sectional analysis of Medicare data","volume":"34","author":"Niznik","year":"2017","journal-title":"Drugs Aging"},{"key":"2025090702525372000_29.3.145.34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40266-017-0513-3","article-title":"Associations between the drug burden index, potentially inappropriate medications and quality of life in residential aged care","volume":"35","author":"Harrison","year":"2018","journal-title":"Drugs Aging"},{"key":"2025090702525372000_29.3.145.35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jamda.2007.02.007","article-title":"The use of a cholinesterase inhibitor review Committee in long-term care","volume":"8","author":"Lee","year":"2007","journal-title":"J Am Med Dir Assoc"},{"key":"2025090702525372000_29.3.145.36","first-page":"313","article-title":"[Sudden Discontinuation of Anti-dementia Drugs in Moderate and Severe Alzheimer's Disease in a Residency for Dependent Elderly People: a Longitudinal Descriptive Pilot Study]","volume":"70","author":"Peyro Saint-Paul","year":"2015","journal-title":"Therapie"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2019-002106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:53:03Z","timestamp":1757238783000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2019-002106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,22]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/ejhpharm-2019-002106"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2019-002106","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]}}}